Extension Study for 2993-112

NCT01789957 · Completed

Last updated 2026-05-28

This study is testing the long-term effects of an investigational treatment on blood sugar control in adults with type 2 diabetes who previously participated in another related trial.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 225 people

Who can join Ages 16–75 · all sexes

Timeline Started 2002-09 · est. completion 2004-06

Where 226 sites · Canada, United States

What this study is testing ClinicalTrials.gov NCT01789957 ↗

Description as written by the study sponsor.

This multicenter, open-label extension study of Protocol 2993-112 is designed to assess long-term glucose control as measured by HbA1c (glycosylated hemoglobin) and to evaluate long-term safety and tolerability in subjects treated with metformin who receive subcutaneously injected AC2993 (10 mcg) administered twice daily. Subjects completing Protocol 2993-112 are eligible to enroll.

Treatments tested

AC2993 also known as Exenatide Drug

4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily

Main thing measured	Change in HbA1c from Day 1 of Protocol 2993-112 to Week 52 (or termination)
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01789957 ↗